Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop

Galectin Therapeutics, Inc. Logo

NORCROSS, Ga., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Nonalcoholic Steatohepatitis (NASH) Workshop hosted by JMP Securities on Thursday, February 27, 2014 in New York, NY. NASH, a progressive liver disease caused by the accumulation of fat in the liver leading to inflammation and fibrosis, is estimated to affect nine to 15 million people, including children, in the United States.

Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer of Galectin Therapeutics, will serve on the NASH diagnostic and therapeutics panel, to be held at Aquavit Restaurant (66 E. 55th Street) from 7:30 a.m. to 11:30 a.m. Eastern Standard Time. The workshop will be followed by one-on-one meetings with company management teams at JMP Securities (450 Park Avenue).

The workshop will address issues and opportunities in the treatment of NASH, the current treatment paradigm, and clinical issues including developments in diagnostics and clinical trial design. The workshop includes a NASH primer led by Dr. Scott L. Friedman, M.D., Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at the Icahn School of Medicine at Mount Sinai.

About NASH

Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, has become a common disease of the liver with the rise in obesity rates, estimated to affect nine to 15 million people, including children, in the U.S. Fatty liver disease is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with fatty liver disease can develop fibrosis, or scarring of the liver, and it is estimated that as many as three million individuals will develop cirrhosis, a severe liver disease where liver transplantation is the only current treatment available. Approximately 6,300 liver transplants are done on an annual basis in the U.S. There are no drug therapies approved for the treatment of liver fibrosis.

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at

CONTACT: Galectin Therapeutics Inc. Peter G. Traber, MD, 678-620-3186 President, CEO, & CMO

Source:Galectin Therapeutics, Inc.